Detection of Malignant Lesions in Cytologically Indeterminate Thyroid Nodules Using a Dual-layer Spectral Detector CT-clinical Nomogram

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 12

PMID 38863637

Authors

Xiaofang Ren

Jiayan Zhang

Zuhua Song

Qian Li

Dan Zhang

Xiaojiao Li

Jiayi Yu

Zongwen Li

Youjia Wen

Dan Zeng

Xiaodi Zhang

Zhuoyue Tang

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the capability of dual-layer detector spectral CT (DLCT) quantitative parameters in conjunction with clinical variables to detect malignant lesions in cytologically indeterminate thyroid nodules (TNs).

Materials And Methods: Data from 107 patients with cytologically indeterminate TNs who underwent DLCT scans were retrospectively reviewed and randomly divided into training and validation sets (7:3 ratio). DLCT quantitative parameters (iodine concentration (IC), NIC (IC nodule/IC thyroid parenchyma), NIC (IC nodule/IC ipsilateral carotid artery), attenuation on the slope of spectral HU curve and effective atomic number), along with clinical variables, were compared between benign and malignant cohorts through univariate analysis. Multivariable logistic regression analysis was employed to identify independent predictors which were used to construct the clinical model, DLCT model, and combined model. A nomogram was formulated based on optimal performing model, and its performance was assessed using receiver operating characteristic curve, calibration curve, and decision curve analysis. The nomogram was subsequently tested in the validation set.

Results: Independent predictors associated with malignant TNs with indeterminate cytology included NIC in the arterial phase, Hashimoto's Thyroiditis (HT), and BRAF V600E (all < 0.05). The DLCT-clinical nomogram, incorporating the aforementioned variables, exhibited superior performance than the clinical model or DLCT model in both training set (AUC: 0.875 vs 0.792 vs 0.824) and validation set (AUC: 0.874 vs 0.792 vs 0.779). The DLCT-clinical nomogram demonstrated satisfactory calibration and clinical utility in both training set and validation set.

Conclusion: The DLCT-clinical nomogram emerges as an effective tool to detect malignant lesions in cytologically indeterminate TNs.

References

Kogai T, Hershman J, Motomura K, Endo T, Onaya T, Brent G . Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells. Endocrinology. 2001; 142(8):3369-79. DOI: 10.1210/endo.142.8.8344. View

de Koster E, de Geus-Oei L, Dekkers O, van Engen-van Grunsven I, Hamming J, Corssmit E . Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev. 2018; 39(2):154-191. DOI: 10.1210/er.2017-00133. View

Song Z, Li Q, Zhang D, Li X, Yu J, Liu Q . Nomogram based on spectral CT quantitative parameters and typical radiological features for distinguishing benign from malignant thyroid micro-nodules. Cancer Imaging. 2023; 23(1):13. PMC: 9878766. DOI: 10.1186/s40644-023-00525-2. View

Piccardo A, Puntoni M, Treglia G, Foppiani L, Bertagna F, Paparo F . Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. Eur J Endocrinol. 2016; 174(5):693-703. DOI: 10.1530/EJE-15-1199. View

Wu Y, Wei C, Wang C, Li N, Zhang P, Dong J . Preoperative Prediction of Cervical Nodal Metastasis in Papillary Thyroid Carcinoma: Value of Quantitative Dual-Energy CT Parameters and Qualitative Morphologic Features. AJR Am J Roentgenol. 2021; 216(5):1335-1343. DOI: 10.2214/AJR.20.23516. View

Vita R, Ieni A, Tuccari G, Benvenga S . The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord. 2018; 19(4):301-309. DOI: 10.1007/s11154-018-9474-z. View

Zarkesh M, Zadeh-Vakili A, Akbarzadeh M, Nozhat Z, Fanaei S, Hedayati M . BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases. Life Sci. 2019; 223:166-173. DOI: 10.1016/j.lfs.2019.03.034. View

Forghani R . An update on advanced dual-energy CT for head and neck cancer imaging. Expert Rev Anticancer Ther. 2019; 19(7):633-644. DOI: 10.1080/14737140.2019.1626234. View

Al-Najami I, Sheta H, Baatrup G . Differentiation between malignant and benign rectal tumors by dual-energy computed tomography - a feasibility study. Acta Oncol. 2019; 58(sup1):S55-S59. DOI: 10.1080/0284186X.2019.1574404. View

10.

Cibas E, Ali S . The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11):1341-1346. DOI: 10.1089/thy.2017.0500. View

11.

Johnson T, Krauss B, Sedlmair M, Grasruck M, Bruder H, Morhard D . Material differentiation by dual energy CT: initial experience. Eur Radiol. 2006; 17(6):1510-7. DOI: 10.1007/s00330-006-0517-6. View

12.

Vriens D, de Wilt J, van der Wilt G, Netea-Maier R, Oyen W, de Geus-Oei L . The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011; 117(20):4582-94. DOI: 10.1002/cncr.26085. View

13.

Huang H, Zhu M, Gao Q, Huang Y, Li W . Comparison of Diagnostic Values of ACR TI-RADS versus C-TIRADS Scoring and Classification Systems for the Elderly Thyroid Cancers. Int J Gen Med. 2023; 16:4441-4451. PMC: 10546997. DOI: 10.2147/IJGM.S429681. View

14.

Chen X, Zhou Q, Wang F, Zhang F, Du H, Zhang Q . Value of V600E in High-Risk Thyroid Nodules with Benign Cytology Results. AJNR Am J Neuroradiol. 2018; 39(12):2360-2365. PMC: 7655409. DOI: 10.3174/ajnr.A5898. View

15.

Sparano C, Verdiani V, Pupilli C, Perigli G, Badii B, Vezzosi V . Choosing the best algorithm among five thyroid nodule ultrasound scores: from performance to cytology sparing-a single-center retrospective study in a large cohort. Eur Radiol. 2021; 31(8):5689-5698. PMC: 8270877. DOI: 10.1007/s00330-021-07703-5. View

16.

Stansifer K, Guynan J, Wachal B, Smith R . Modifiable risk factors and thyroid cancer. Otolaryngol Head Neck Surg. 2015; 152(3):432-7. DOI: 10.1177/0194599814564537. View

17.

Marletta S, Salatiello M, Pantanowitz L, Bellevicine C, Bongiovanni M, Bonoldi E . Delphi expert consensus for whole slide imaging in thyroid cytopathology. Cytopathology. 2023; 34(6):581-589. DOI: 10.1111/cyt.13279. View

18.

Durante C, Grani G, Lamartina L, Filetti S, Mandel S, Cooper D . The Diagnosis and Management of Thyroid Nodules: A Review. JAMA. 2018; 319(9):914-924. DOI: 10.1001/jama.2018.0898. View

19.

Nemec U, Nemec S, Novotny C, Weber M, Czerny C, Krestan C . Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. Eur Radiol. 2012; 22(6):1357-65. DOI: 10.1007/s00330-012-2385-6. View

20.

Zhang T, Hou F, Liu D, Zhou H, Sun Y, Deng X . Association of Hashimoto's thyroiditis and anti-thyroid antibodies with oral lichen planus: A cross-sectional study. Front Immunol. 2022; 13:967988. PMC: 9424685. DOI: 10.3389/fimmu.2022.967988. View